Skip to main content
SpringerLink
Log in

Acromegaly: historical perspectives and current therapy

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Soon after the initial description of acromegaly in the late 19th century, neurosurgeons performed the first operative procedures for the disease. Transcranial procedures eventually yielded to the transsphenoidal approach. Reasonably effective medical therapy was introduced in the 1970s and pharmacological progress continues to be realized. It is now recognized that excess growth hormone is associated with significant morbidity and mortality and that biochemical remission improves outcome. Although medical and radiation treatments offer useful adjuncts, surgery provides optimal results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marie P: Sur deux cas d'acromeglie: hypertophie singuliere, non congenitale, des extremites superieures, inferieures et cephalique. Rev Med Liege 6: 297–333, 1886

    Google Scholar 

  2. Verga A:Caso singolare di prosopectasia. Rend R 1st Lombardo Classe Sc Mat Nat 1: 111–117, 1864

  3. Brigidi V: Studii anatomo-patologici sopra un uomo divenuto stranamente deforme per cronica infermita. Arch Scuola Anat Patol Firenze 65–92, 1881

  4. Marie P, Marinesco G: Sur l'anatomie pathologique de l'acromegalie. Arch Med Exp Anat Pathol 3: 539–565, 1891

    Google Scholar 

  5. Massalongo R: Sull'acromegalia. Riforma Med 8: 74, 1892

    Google Scholar 

  6. Benda C: Beitrage zur normalen und pathologischen histologie der menschlichen hypophysis cerebri. Klin Wochenschr 36: 1205, 1900

    Google Scholar 

  7. Cushing H: Partial hypophysectomy for acromegaly: with remarks on the function of the hypophysis. Ann Surg 50: 1002–1017, 1909

    Google Scholar 

  8. Evans HM, Long JA: The effect of the anterior lobe of the pituitary administered intra-peritoneally upon growth, maturity and oestrus cycle of the rat. Anat Rec 21: 62, 1921

    Google Scholar 

  9. Caton R, Paul FT: Notes on a case of acromegaly treated by operation. Br Med J 2: 1421–1423, 1893

    Google Scholar 

  10. Horsley V: Address in surgery on the technic of operation on the central nervous system. Br Med J 2: 411–423, 1906

    Google Scholar 

  11. Schloffer H: Erfolgreiche Operationen eines Hypophentamors auf Nasalem Wage. Wien Klin Wochenschr 20: 621–624, 1907

    Google Scholar 

  12. Hochenegg J: Operat geheilte Akromegalie bei Hypophysentumor. Verh Dtsch Ges Chir 37: 80–85, 1908

    Google Scholar 

  13. Halstead AE: The operative treatment of tumors of the hypophysis. Surg Gynecol Obstet 10: 494, 1910

    Google Scholar 

  14. Halstead AE: Remarks on the operative treatment of tumors of the hypophysis.With the report of two cases operated on by an oronasal method. Trans Am Surg Assoc 28: 73–93, 1910

    Google Scholar 

  15. Hirsch O: Endonasal method of removal of hypohyseal tumors. JAMA 5: 772–774, 1910

    Google Scholar 

  16. Kanavel AB: The removal of tumors of the pituitary body by an infranasal route. JAMA 53: 1704–1707, 1909

    Google Scholar 

  17. Kocher T: Ein Fall von Hypophysis-Tumor mit operativer Heilung. Dtsch Z Mund Kiefer Gesichtschir 100: 13–37, 1909

    Google Scholar 

  18. Henderson WR: The pituitary adenomata. A follow-up study of the surgical results in 338 cases (Dr Harvey Cushing's series). Br J Surg 26: 911–921, 1939

    Google Scholar 

  19. Rosegay H: Cushing's legacy to transsphenoidal surgery. J Neurosurg 54: 448–454, 1981

    Google Scholar 

  20. Glick SM, Roth J, Yalow RS, Berson SA: Immunoassay of human growth hormone in plasma. Nature 199: 784–787, 1963

    Google Scholar 

  21. Hunter WM, Greenwood FC: Preparation of iodine-131I labelled human growth hormone in plasma. Nature 194: 495, 1962

    Google Scholar 

  22. Utiger RD, Parker ML, Daughaday WH: Studies on human growth hormone: a radioimmunoassay for human growth hormone. J Clin Invest 41: 254–261, 1962

    Google Scholar 

  23. Lawrence JH, Tobias CA, Born JL, Sangalli R, Carlson RA, Linfoot JH: Heavy particle therapy in acromegaly. Acta Radiol 58: 337–347, 1962

    Google Scholar 

  24. Sheline GE, Goldberg MB, Feldman R: Pituitary irradiation for acromegaly. Radiology 76: 70–75, 1961

    Google Scholar 

  25. Pistenma DA, Goffinet DR, Bagshaw MA, Hanbery JW, Eltringham JR: Treatment of acromegaly withmegavoltage radiation therapy. Int J Radiat Oncol Biol Phys 1: 885–893, 1976

    Google Scholar 

  26. Kramer S: Indications for, and results of, treatment of pituitary tumors by external radiation. In: Kohler PO, Ross GT (eds) Diagnosis and Treatment of Pituitary Tumors. Excerpta Medica/American Elsevier, New York, 1973, pp 217–233

    Google Scholar 

  27. Roth J, Glick SM, Hollander CS: Acromegaly and other disorders of growth hormone secretion. Ann Intern Med 66: 760–788, 1967

    Google Scholar 

  28. Beck P, Schalch DS, Parker ML, Kipnis DM, Daughaday WH: Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly. J Lab Clin Med 66: 366–379, 1965

    Google Scholar 

  29. Sheline GE, Wara WM: Radiation therapy for acromegaly and nonsecretory chromophobe adenomas of the pituitary. In: Seydel HG (ed) Tumors of the Nervous System. John Wiley, New York, 1975, pp 117–132

    Google Scholar 

  30. Lamberg BA, Kivikangas V, Vartianen J, Raitta C, Pelkonen R: Conventional pituitary irradiation in acromegaly. Effect on growth hormone and TSH secretion. Acta Endocrinol (Copenh) 82: 267–281, 1976

    Google Scholar 

  31. Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly AS, Mortimer CH, Phenekos C, Tunbridge WM, Weightman D: Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 2: 581–584, 1973

    Google Scholar 

  32. Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Tunbridge WM, Thorner MO, Hall R: Growth hormone release inhibiting hormone in acromegaly. Br Med J 1: 352–355, 1974

    Google Scholar 

  33. Besser GM, Mortimer CH, McNeilly AS, Thorner MO, Batistoni GA, Bloom SR, Kastrup KW, Hanssen KF, Hall R, Coy DH, Kastin AJ, Schally AV: Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones. Br Med J 4: 622–627, 1974

    Google Scholar 

  34. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless R: SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140, 1982

    Google Scholar 

  35. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F: Inhibitory effect of L-dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 35: 941–943, 1972

    Google Scholar 

  36. Liuzzi A, Chiodini PG, Botalla L, Silvestrini F, Muller EE: Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses. J Clin Endocrinol Metab 39: 871–876, 1974

    Google Scholar 

  37. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 38: 910–912, 1974

    Google Scholar 

  38. Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, Sanders P, Mason AS, Besser GM: Bromocriptine treatment of acromegaly. Br Med J 1: 299–303, 1975

    Google Scholar 

  39. Pearson OH, Thomas CH, Kaufman B, Shealy CN, Collins WF, Jane JA, Jackson CCR: Pituitary ablation in the treatment of diabetic retinopathy. In: Goldberg MF, Find SL (eds) Symposium on Treatment of Diabetic Retinopathy. Government Printing Office, Warrenton, Virginia, 1968, pp 331–339

  40. Guiot G, Bouche J, Oproiu A: (Indications of the transsphenoidal approach to pituitary adenomas. Experience with 165 operations). Presse Med 75: 1563–1568, 1967

    Google Scholar 

  41. Guiot G, Derome P: (Indications for trans-sphenoid approach in neurosurgery. 521 cases). Ann Med Interne (Paris) 123: 703–712, 1972

    Google Scholar 

  42. Guiot G: Transsphenoidal approach in surgical treatment of pituitary adenomas: general principles and indications in nonfunctioning adenomas. In:Kohler PO, Ross GT(eds) Diagnosis and Treatment of Pituitary Tumors. American Elsevier, New York, 1973, pp 159–178

    Google Scholar 

  43. Hardy J, Wigser SM: Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control. J Neurosurg 23: 612–619, 1965

    Google Scholar 

  44. Hardy J: (Surgery of the pituitary gland, using the transsphenoidal approach. Comparative study of 2 technical methods). Union Med Can 96: 702–712, 1967

    Google Scholar 

  45. Hardy J: Transsphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 16: 185–217, 1969

    Google Scholar 

  46. Hardy J: Transsphenoidal hypophysectomy. J Neurosurg 34: 582–594, 1971

    Google Scholar 

  47. Laws ER Jr, Scheithauer BW, Carpenter S, Randall RV, Abboud CF: The pathogenesis of acromegaly. Clinical and immunocytochemical analysis in 75 patients. J Neurosurg 63: 35–38, 1985

    Google Scholar 

  48. Colao A, Merola B, Ferone D, Lombardi G: Acromegaly. J Clin Endocrinol Metab 82: 2777–2781, 1997

    Google Scholar 

  49. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M: Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 80: 3395–3402, 1995

    Google Scholar 

  50. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12: 71–79, 1980

    Google Scholar 

  51. Etxabe J, Gaztambide S, Latorre P, Vazquez JA: Acromegaly: an epidemiological study. J Endocrinol Invest 16: 181–187, 1993

    Google Scholar 

  52. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR: Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 59: 55–62, 1990

    Google Scholar 

  53. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223: 327–335, 1988

    Google Scholar 

  54. Wright AD, Hill DM, Lowy C, Fraser TR: Mortality in acromegaly. Q J Med 39: 1–16, 1970

    Google Scholar 

  55. Bishop PMF, Briggs JH: Anterior pituitary gland. Lancet i: 735, 1958

    Google Scholar 

  56. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J: Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group (see comments). Clin Endocrinol (Oxf) 49: 441-445, 1998

    Google Scholar 

  57. Ituarte EM, Petrini J, Hershman JM: Acromegaly and colon cancer. Ann Intern Med 101: 627–628, 1984

    Google Scholar 

  58. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83: 2730–2734, 1998

    Google Scholar 

  59. Thapar K, Kovacs K, Laws ER: The classification and molecular biology of pituitary adenomas. Adv Tech Stand Neurosurg 22: 3–53, 1995

    Google Scholar 

  60. Furlanetto RW, Underwood L, Van Wyk JJ, D'Ercole AJ: Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 60: 648, 1977

    Google Scholar 

  61. Bates AS, Van't Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 86: 293–299, 1993

    Google Scholar 

  62. Clayton RN: New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J Endocrinol 155: S23–29; discussion S31-32, 1997

    Google Scholar 

  63. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly (see comments). J Clin Endocrinol Metab 83: 3419–3426, 1998

    Google Scholar 

  64. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526–529, 2000

    Google Scholar 

  65. Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL, Edwards CR: How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol (Oxf) 20: 401–408, 1984

    Google Scholar 

  66. Eastman RC, Gorden P, Roth J: Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 48: 931–940, 1979

    Google Scholar 

  67. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW: Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93: 6–9, 2000

    Google Scholar 

  68. Laws ER, Vance ML, Thapar K: Pituitary surgery for the management of acromegaly. Horm Res 53: 71–75, 2000

    Google Scholar 

  69. Laws ER Jr, Vance ML: Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am 10: 327–336, 1999

    Google Scholar 

  70. Kim MS, Lee SI, Sim JH: Gamma Knife radiosurgery for functioning pituitary microadenoma. Stereotact Funct Neurosurg 72: 119–124, 1999

    Google Scholar 

  71. Kim SH, Huh R, Chang JW, Park YG, Chung SS: Gamma Knife radiosurgery for functioning pituitary adenomas. Stereotact Funct Neurosurg 72: 101–110, 1999

    Google Scholar 

  72. Colao A, Lombardi G: Growth-hormone and prolactin excess. Lancet 352: 1455–1461, 1998

    Google Scholar 

  73. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374–378, 1998

    Google Scholar 

  74. Jaffe CA, Barkan AL: Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21: 713–735, 1992

    Google Scholar 

  75. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D: Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139: 516–521, 1998

    Google Scholar 

  76. Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22: 40–47, 1999

    Google Scholar 

  77. Wass JA, Thorner MO, Morris DV, Rees LH, Mason AS, Jones AE, Besser GM: Long-term treatment of acromegaly with bromocriptine. Br Med J 1: 875–878, 1977

    Google Scholar 

  78. Jaffe CA, Barkan AL: Acromegaly. Recognition and treatment. Drugs 47: 425–445, 1994

    Google Scholar 

  79. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G: Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82: 518–523, 1997

    Google Scholar 

  80. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL: Octreotide as primary therapy for acromegaly (see comments). J Clin Endocrinol Metab 83: 3034–3040, 1998

    Google Scholar 

  81. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 334: 246–254, 1996

    Google Scholar 

  82. al-Maskari M, Gebbie J, Kendall-Taylor P: The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 45: 415–421, 1996

    Google Scholar 

  83. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM: Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly (published erratum appears in Clin Endocrinol (Oxf) 48: 673, 1998). Clin Endocrinol (Oxf) 48: 311–316, 1998

    Google Scholar 

  84. Gillis JC, Noble S, Goa KL: Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53: 681–699, 1997

    Google Scholar 

  85. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC: Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80: 3267–3272, 1995

    Google Scholar 

  86. Newman CB: Medical therapy for acromegaly. Endocrinol Metab Clin North Am 28: 171–190, 1999

    Google Scholar 

  87. Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P: Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79: 145–151, 1994

    Google Scholar 

  88. Giusti M, Gussoni G, Cuttica CM, Giordano G: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group (see comments). J Clin Endocrinol Metab 81: 2089–2097, 1996

    Google Scholar 

  89. Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, Biondi B, Sacca L, Lombardi G: Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 77: 790–793, 1993

    Google Scholar 

  90. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P: The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf) 30: 619–625, 1989

    Google Scholar 

  91. Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, Pumar A, Astorga R: Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 14: 17–23, 1991

    Google Scholar 

  92. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G: Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84: 527–532, 1999

    Google Scholar 

  93. Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M: Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 83: 1506–1509, A1508, 1999

    Google Scholar 

  94. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, Harris AG, Lubetzki J: Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 113: 921–925, 1990

    Google Scholar 

  95. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G: Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84: 17–23, 1999

    Google Scholar 

  96. Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, De Brasi D, Scarpa R, Oriente P, Lombardi G: Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 83: 2121–2125, 1998

    Google Scholar 

  97. Caron P, Morange-Ramos I, Cogne M, Jaquet P: Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide (see comments). J Clin Endocrinol Metab 82: 18–22, 1997

    Google Scholar 

  98. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ: In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J Biol Chem 269: 20806, 1994

    Google Scholar 

  99. Parkinson C, Trainer PJ: Growth hormone receptor antagonists therapy for acromegaly. Best Pract Res Clin Endocrinol Metab 13: 419–430, 1999

    Google Scholar 

  100. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ: Treatment of acromegaly with the growth hormonereceptor antagonist pegvisomant (see comments). N Engl J Med 342: 1171–1177, 2000

    Google Scholar 

  101. Jaffe CA, Friberg RD, Barkan AL: Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 92: 695–701, 1993

    Google Scholar 

  102. Jankowski R, Auque J, Simon C, Marchal JC, Hepner H, Wayoff M: Endoscopic pituitary tumor surgery. Laryngoscope 102: 198–202, 1992

    Google Scholar 

  103. Jho HD, Carrau RL: Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 87: 44–51, 1997

    Google Scholar 

  104. Elias WJ, Chadduck JB, Alden TD, Laws ER Jr: Frameless stereotaxy for transsphenoidal surgery (see comments). Neurosurgery 45: 271–275; discussion 275-277, 1999

    Google Scholar 

  105. Weiss MH: Transnasal transsphenoidal approach. In: Apuzzo MLJ (ed) Surgery of the Third Ventricle.Williams and Wilkins, Baltimore, 1987, pp 476–494

    Google Scholar 

  106. Mason RB, Nieman LK, Doppman JL, Oldfield EH: Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function (see comments). J Neurosurg 87: 343–351, 1997

    Google Scholar 

  107. Laws ER Jr: Transsphenoidal removal of craniopharyngioma. Pediatr Neurosurg 21: 57-63, 1994

    Google Scholar 

  108. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45: 407–413, 1996

    Google Scholar 

  109. Davis DH, Laws ER Jr Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM, Schleck C: Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 79: 70–75, 1993

    Google Scholar 

  110. Fahlbusch R, Honegger J, Buchfelder M: Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 155: S53–55, 1997

    Google Scholar 

  111. Fahlbusch R, Honegger J, Buchfelder M: Surgical management of acromegaly. Endocrinol Metab Clin North Am 21: 669–692, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA

    John A. Jane Jr., Kamal Thapar & Edward R. Laws Jr.

Authors
  1. John A. Jane Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamal Thapar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward R. Laws Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jane, J.A., Thapar, K. & Laws, E.R. Acromegaly: historical perspectives and current therapy. J Neurooncol 54, 129–137 (2001). https://doi.org/10.1023/A:1012949214960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012949214960

Search

Navigation